SORAGNI LAB
  • Home
  • Research Overview
    • Tumor organoid screenings for biology ​and precision medicine
    • Protein aggregation in cancer ​initiation and progression >
      • ReACp53
  • People
    • PI Bio
    • Open Positions
  • Publications
  • Funding
  • Lab News
    • News: Spring & Summer 21
    • News: Winter 20/21
    • Older News
  • Contact
  • Home
  • Research Overview
    • Tumor organoid screenings for biology ​and precision medicine
    • Protein aggregation in cancer ​initiation and progression >
      • ReACp53
  • People
    • PI Bio
    • Open Positions
  • Publications
  • Funding
  • Lab News
    • News: Spring & Summer 21
    • News: Winter 20/21
    • Older News
  • Contact

Protein aggregation
in cancer ​initiation and progression

We are investigating the role of p53 aggregation in cancer onset and progression. We exploit p53 aggregation for therapeutic intervention using peptide drugs, and are testing combinatorial regimens with traditional chemotherapy and other targeted agents. In addition, we are studying the role of protein aggregation in cancer more broadly, by identifying which proteins misfold and accumulate in different cancers, in which conditions this happens and design therapeutic peptides to target them for cancer therapy.
 A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas. Soragni et al, Cancer Cell, 2016
p53 reactivation: Chasing the “untargetable” to circumvent resistance. Soragni, 2021, Overcoming Ovarian Cancer Chemoresistance, Elsevier
Interested in ReACp53?